Colorectal cancer | News | Media | Updates

Colorectal cancer is the cancer of the colon, the final part of the digestive tract. Cancer usually starts in the inner lining of the colon or rectum.

May 23, 2022

Seagen announced cORR in Phase 2 clinical trial of Tukysa plus trastuzumab.

Seagen has announced the Phase 2 MOUNTAINEER clinical trial, which evaluates the efficacy of Tukysa (tucatinib) in combination with trastuzumab in adult patients with HER2-positive metastatic colorectal cancer (mCRC). Seagen announced that this clinical trial would become the basis for the supplemental New Drug Application to the US Food and Drug Administration.

MOUNTAINEER is a Phase 2 clinical trial that enrolled 117 patients with HER2-positive metastatic or unresectable colorectal cancer. The primary endpoint was confirmed objective response rate, 38.1% of patients showed cORR. The median duration of response was 12.4 months.


 

0 comments

Recent Posts

See All